Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Ribon Therapeutics

Ribon Therapeutics
2015 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
Series B LATEST DEAL TYPE
$65M LATEST DEAL AMOUNT
10 INVESTORS
Description

Developer of a biotech platform intended to block cancer cell's fundamental ability to survive under stress. The company's offerings include discovery and development of first-in-class small molecule inhibitors or each enzyme in the target family, enabling doctors to help treat patients suffering from cancer.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 35 Cambridgepark Drive
  • Cambridge, MA 02140
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ribon Therapeutics’s full profile, request a free trial.

Ribon Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 04-Jan-2019 $65M 00000 00000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 10-Oct-2017 000.00 000.00 000.00 Completed Stealth
To view this company’s complete deal history including valuation and funding, request access »

Ribon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Ribon Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN 00 000.00 0000000000 0 000.00
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
00000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
0000000000 0000000 Venture Capital-Backed Seattle, WA 00 0000 00000000000 0000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
To view this company’s complete list of competitors, request access »

Ribon Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Celgene Corporation Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ribon Therapeutics Executive Team (10)

Name Title Board
Seat
Contact
Info
Victoria Richon Ph.D President, Chief Executive Officer & Board Member
Paul Chang Ph.D Scientific Co-Founder
Tim Mitchison Ph.D Scientific Co-Founder
W. Kraus Ph.D Scientific Co-Founder
Kevin Kuntz Ph.D Vice President, Molecular Discovery

1 Former Executive

You’re viewing 5 of 10 executives. Get the full list »

Ribon Therapeutics Board Members (8)

Name Representing Role Since Contact
Info
Anja K├Ânig Ph.D Novartis Venture Fund Board Member 000 0000
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
James Audia Ph.D Self Board Member 000 0000
Jonathan Root MD US Venture Partners Board Member 000 0000
Laurence Lasky Ph.D The Column Group Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »